Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Biologic injection for severe asthma approved in Scotland

A biologic injection intended for the treatment of severe eosinophilic asthma has been accepted for restricted use by the Scottish Medicines Consortium (SMC), providing another option for patients who fail to respond to other treatments.

Use of benralizumab (Fasenra; AstraZeneca) will be restricted to patients with severe eosinophilic asthma that is inadequately controlled despite taking high-dose inhaled corticosteroids plus long-acting beta-agonists.

“This SMC decision is fantastic news for severe asthma patients in Scotland, providing access to another targeted treatment that has the potential to improve long-term control of the disease,” said Brian Lipworth from the Scottish Centre for Respiratory Research at Ninewells Hospital and Medical School in Dundee, Scotland.

“In my clinical experience, standard-of-care therapy may not prevent asthma exacerbations, A&E visits or hospitalisations for people with severe asthma.”

The SMC noted that benralizumab, which is administered once every four weeks for the first three doses and then every eight weeks afterwards, may be more convenient for patients and carers. Other biologics for severe eosinophilic asthma are given every four weeks.

It is estimated that around 5,500 people in Scotland could be eligible for treatment.

Benralizumab was approved by the National Institute for Health and Care Excellence in January 2019.


Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206661

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.